Selection Strategies and Practical Application of BRAF V600E-Mutated Non–Small Cell Lung Carcinoma

PURPOSE: The incidence of BRAF V600E mutation in non–small cell lung carcinoma (NSCLC) is lower than 2%, which poses difficulties in finding legitimate patients for targeted therapy. We investigated the predictive factors pertaining to BRAF V600E and the effectiveness of the VE1 antibody as a screen...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Inwoo, Choi, Yoon-La, Lee, Hyunwoo, Hwang, Soohyun, Lee, Boram, Yang, Hobin, Chelakkot, Chaithanya, Han, Joungho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296927/
https://www.ncbi.nlm.nih.gov/pubmed/34844291
http://dx.doi.org/10.4143/crt.2021.843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296927/
https://www.ncbi.nlm.nih.gov/pubmed/34844291
http://dx.doi.org/10.4143/crt.2021.843

Ejemplares similares